Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Akamai Technologies, Inc. (AKAM) vs Gilead Sciences, Inc. (GILD) Price & Performance

Akamai Technologies, Inc.Trade
Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

Akamai Technologies, Inc. vs Gilead Sciences, Inc. — how do they compare? Akamai Technologies, Inc. trades at $123.68 (market cap $16.77B), while Gilead Sciences, Inc. trades at $135.97 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 10× Akamai Technologies, Inc.'s market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Akamai Technologies, Inc. pays none. Which is the better fit depends on your goals.

AKAMGILD
Market Cap
$16.77B$168.35B
Sector
TechnologyHealth
52-Week High
$161.14$155.80
52-Week Low
$71.97$110.56
Enterprise Value
$22.75B$191.42B
Dividend Yield
2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Akamai Technologies, Inc.

Akamai Technologies (AKAM) trades at $123.20, up 4.72% with strong quarterly earnings beats and accelerating cloud infrastructure growth. The stock shows mixed technical signals with bearish moving averages but neutral oscillators. Recent Q2 2026 results exceeded expectations with $1.59 EPS versus $1.57 estimate, driven by 39% growth in Cloud Infrastructure Services. However, net income margins have declined from 14.47% in 2022 to 9.51% currently due to increased infrastructure investments.

Akamai presents a compelling growth story in AI and cybersecurity markets with analyst consensus target of $150.11 suggesting 22% upside potential. Key risks include margin pressure from heavy infrastructure spending and competitive threats in cloud services. The balanced analyst rating distribution (47% Buy, 49% Hold) reflects cautious optimism about the company's strategic positioning amid ongoing profitability challenges.

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.

Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Akamai Technologies, Inc.

Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.

Read more on AKAM

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD